remibrutinib

Small molecule

Also known as LOU064

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Spontaneous Urticaria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Multiple Sclerosis · Phase 3Hidradenitis Suppurativa · Phase 3Secondary Progressive Multiple Sclerosis · Phase 3

Also approved (5)
US
  • Symptomatic dermographism (SD) in adults inadequately controlled by H1 antihistamines (supplemental indication, NDA218436 S-1)
Product first approved 2025Outside this platform's coveragenovartis.com
CA
  • RHAPSIDO (remibrutinib tablets) is indicated for: • the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
Product first approved 2026Health Canada
EU
  • Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
Product first approved 2026EMA
UK
  • Chronic spontaneous urticaria (CSU) in adults inadequately controlled by H1 antihistamines
novartis.com
CN
  • Chronic spontaneous urticaria (CSU) in adults inadequately controlled by H1 antihistamines
novartis.com

Development in Generalized Myasthenia Gravis stopped (2026-10-27) after a negative readout. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (22)
Chronic Spontaneous Urticaria
NCT07816328 · Novartis Pharmaceuticals
2026-09-21 – 2028-05-24 · Chronic Spontaneous Urticaria
What this study did
NCT05513001 · Novartis Pharmaceuticals
2022-12-09 – 2027-08-02 · Chronic Spontaneous Urticaria
What this study did
NCT06868212 · Novartis Pharmaceuticals
2025-07-11 – 2027-05-17 · Chronic Spontaneous Urticaria (CSU)
What this study did
NCT05048342 · Novartis Pharmaceuticals
2022-01-15 – 2023-12-09 · Chronic Spontaneous Urticaria
What this study did
Hidradenitis Suppurativa
NCT07665437 · Novartis Pharmaceuticals
2026-07-10 – 2031-10-15 · Hidradenitis Suppurativa
What this study did
NCT06840392 · Novartis Pharmaceuticals
2025-03-20 – 2027-10-21 · Hidradenitis Suppurativa
What this study did
NCT06799000 · Novartis Pharmaceuticals
2025-01-31 – 2027-10-04 · Hidradenitis Suppurativa
What this study did
Multiple Sclerosis
NCT06846281 · Novartis Pharmaceuticals
2025-06-23 – 2031-06-25 · Relapsing Multiple Sclerosis
What this study did
Secondary Progressive Multiple Sclerosis
NCT07225504 · Novartis Pharmaceuticals
2025-11-11 – 2034-01-02 · Secondary Progressive Multiple Sclerosis (SPMS)
What this study did
Other / comorbidity
NCT06744920 · Novartis Pharmaceuticals
2025-02-07 – 2033-02-26 · Generalized Myasthenia Gravis
What this study did
NCT07456891 · Novartis Pharmaceuticals
2026-04-16 – 2033-01-30 · Indication of the Parent Protocol
What this study did
NCT07700056 · Novartis Pharmaceuticals
2026-08-24 – 2030-04-15 · Chronic Pruritus of Unknown Origin
What this study did
NCT07811869 · Novartis Pharmaceuticals
2026-10-07 – 2030-01-03 · Chronic Pruritus of Unknown Origin
What this study did
NCT07768371 · Novartis Pharmaceuticals
2026-08-27 – 2029-12-31 · IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
What this study did
NCT05976243 · Novartis Pharmaceuticals
2023-12-07 – 2029-06-15 · Chronic Inducible Urticaria
What this study did
Phase 2 (9)
Chronic Spontaneous Urticaria
NCT06865651 · Novartis Pharmaceuticals
2025-05-22 – 2027-09-28 · Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
What this study did
NCT04109313 · Novartis Pharmaceuticals
2019-10-24 – 2022-09-09 · Chronic Spontaneous Urticaria
What this study did
NCT03926611 · Novartis Pharmaceuticals
2019-06-06 – 2021-04-15 · Chronic Spontaneous Urticaria
What this study did
Hidradenitis Suppurativa
NCT03827798 · Novartis Pharmaceuticals
2019-02-27 – 2026-09-11 · Hidradenitis Suppurativa
What this study did
Secondary Progressive Multiple Sclerosis
NCT07222956 · Moein Amin
2027-03-01 – 2030-12-30 · Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
What this study did
Other / comorbidity
NCT07681271 · Novartis Pharmaceuticals
2026-07-30 – 2027-12-07 · Papulopustular Rosacea
What this study did
NCT05432388 · Novartis Pharmaceuticals
2022-10-12 – 2025-03-11 · Allergy, Peanut
What this study did
NCT04035668 · Novartis Pharmaceuticals
2019-07-12 – 2021-11-23 · Sjögren Syndrome
What this study did
NCT03944707 · Novartis Pharmaceuticals
2019-07-18 – 2020-04-27 · Asthma
What this study did
Phase 1 (4)
Hidradenitis Suppurativa
NCT07855276 · Novartis Pharmaceuticals
2026-10-29 – 2027-12-27 · Hidradenitis Suppurativa
What this study did
Other / comorbidity
NCT07032272 · Novartis Pharmaceuticals
2025-07-23 – 2025-10-14 · Autoimmune and Chronic Inflammatory Diseases
What this study did
NCT05753592 · Novartis Pharmaceuticals
2022-10-31 – 2023-12-17 · Hepatic Impairment
What this study did
NCT03918980 · Novartis Pharmaceuticals
2016-08-18 – 2020-01-27 · Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Spontaneous Urticaria: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Remibrutinib: this drugApprovedSmall moleculeBruton's tyrosine kinase (BTK)Reliable signalNo reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)
NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results).
BarzolvolimabPhase 3Monoclonal antibodyKITPartial signal
NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
Bexobrutideg
Phase 3(overall)
Small moleculeBruton's tyrosine kinase (BTK)
not yet graded(overall)
No reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
HRS-3095Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BriquilimabPhase 1/2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
Girocitinib
—(overall)
Small moleculeTYK2/JAK1Reliable signalNo reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKITnot yet gradedNo reviewed efficacy summary in this indication
SHR-3095
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow remibrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
February 2027 (1)
Phase 3Chronic Spontaneous UrticariaActive not recruiting
Est. primary completion 2027-02-22 · NCT06868212 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-05-17 · NCT06799000 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-06-03 · NCT06840392 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Chronic Spontaneous UrticariaRecruiting
Est. primary completion 2027-08-23 · NCT06865651 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Hidradenitis SuppurativaRecruiting
Est. primary completion 2027-11-29 · NCT07855276 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Papulopustular RosaceaRecruiting
Est. primary completion 2027-12-07 · NCT07681271 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 3Generalized Myasthenia GravisActive not recruitingDiscontinued in this indication
Est. primary completion 2028-02-25 · NCT06744920 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Chronic Spontaneous UrticariaRecruiting
Est. primary completion 2028-05-24 · NCT07816328 · CT.gov ↗
What to watch
2029 (4)
February 2029 (1)
Phase 3Chronic Pruritus of Unknown OriginRecruiting
Est. primary completion 2029-02-26 · NCT07811869 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg AllergyRecruiting
Est. primary completion 2029-03-30 · NCT07768371 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Multiple SclerosisRecruiting
Est. primary completion 2029-07-25 · NCT06846281 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Chronic Pruritus of Unknown OriginRecruiting
Est. primary completion 2029-12-19 · NCT07700056 · CT.gov ↗
What to watch
2030 (2)
October 2030 (1)
Phase 2Multiple SclerosisNot yet recruiting
Est. primary completion 2030-10-30 · NCT07222956 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Multiple SclerosisRecruiting
Est. primary completion 2030-12-03 · NCT07225504 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3Hidradenitis SuppurativaRecruiting
Est. primary completion 2031-10-15 · NCT07665437 · CT.gov ↗
What to watch
2033 (1)
January 2033 (1)
Phase 3Indication of the Parent ProtocolRecruiting
Est. primary completion 2033-01-30 · NCT07456891 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026ApprovalFDA approves Rhapsido for symptomatic dermographism
US, FDA · Novartis · Source ↗
1 September 2026Topline resultNovartis reports the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing MS met their primary endpoint
Novartis · Source ↗
18 February 2026Topline resultPositive topline results from Phase III RemIND trial in CIndU
18 February 2026Filing submittedsNDA submitted to FDA for symptomatic dermographism
US, FDA · Source ↗